- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Biomarker, Review, Journal: Hypouricemia: what the practicing rheumatologist should know about this condition. (Pubmed Central) - Nov 12, 2020 The rheumatologist is considered an expert in the metabolism of urate and its associated pathological conditions. Therefore, specialists must recognize hypouricemia as a biomarker of various pathological and potentially harmful conditions, highlighting the importance of conducting a deeper clinical investigation to reach a more accurate diagnosis and treatment.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Journal: Keratocytes promote corneal neovascularization through VEGFr3 induced by PPARα-inhibition. (Pubmed Central) - Nov 12, 2020 As the peroxisome proliferator - activated receptor alpha (PPARα) agonist, fenofibrate has been widely used to be a good lipid-regulating drug in the clinical application...However, the results in PPARα-/- CNV and keratocytes model were opposite. Our results suggest that keratocytes could promote the expression of VEGFr3 and MMP13, and CNV formation through PPARα downregulation.
- |||||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Become part of the dry eye digital dialogue with Alcon by going to https://t.co/w0j9ck6jbn to register! #Ad #Alcon, #SystaneiLux, #Expandyourpractice, #MGD, #RootCause, #DryEye, #iluviLux, #SeeBrilliantly, #DEEP #optometry #ophthalmology (Twitter) - Nov 11, 2020
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Clinical, Journal, Monotherapy: A Four Month Randomized Controlled Trial on the Efficacy of Once-daily Fenofibrate Monotherapy in Persons with Spinal Cord Injury. (Pubmed Central) - Nov 7, 2020 In the same comparison at Mo4, the treatment group maintained a 40% (±20%; p < 0.05) reduction in serum TG concentration, had an 18% in reduction in LDL-C (±12%; p < 0.05) and a 23% (±23%; p < 0.05) increase in HDL-C. Fenofibrate monotherapy for Mo2 and Mo4 initiated in persons with SCI resulted in a robust and favorable change in the serum lipoprotein profile and ratios, suggesting reduced risk for cardiovascular disease.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Journal: Fenofibrate prevents iron induced activation of canonical Wnt/β-catenin and oxidative stress signaling in the retina. (Pubmed Central) - Nov 5, 2020 In addition, treatment of RPE cells with peroxisome proliferator-activated receptor (PPAR) α-agonist fenofibrate prevented iron-induced activation of oxidative stress and Wnt/β-catenin signaling by chelating the iron. The role of fenofibrate, an FDA-approved drug for hyperlipidemia, as an iron chelator has potentially significant therapeutic impact on iron associated degenerative diseases.
- |||||||||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Clinical, Journal: Perspective on the Budgetary Impact of FP/FORM pMDI on Treatment and Management of Exacerbation in Moderate-to-Severe Asthma Patients in Singapore. (Pubmed Central) - Nov 1, 2020 The use of fluticasone propionate/formoterol fumarate dihydrate (FP/FORM) pressurized metered-dose (pMDI, Flutiform), a type of inhaled corticosteroid (ICS) and long-acting β2 agonist (LABA) fixed-dose combination, has been associated with lower oral corticosteroid-requiring exacerbation rates than other ICS/LABA fixed-dose combinations, fluticasone propionate/salmeterol xinafoate (FP/SAL) and budesonide/formoterol fumarate (BUD/FORM)...In the scenario where patients switched from BUD/FORM, greater drug (S$2,572,797) and exacerbation management (S$256,781) cost savings were observed over 5 years. The analysis provides a perspective that the increased access to FP/FORM could help achieve drug and exacerbation cost savings for the treatment of moderate-to-severe asthma.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Journal: Satellite glial cells promote regenerative growth in sensory neurons. (Pubmed Central) - Oct 26, 2020 The PPARα agonist fenofibrate rescues the impaired axon regeneration in mice lacking Fasn in SGC. These results indicate that PPARα activity downstream of FASN in SGC contributes to promote axon regeneration in adult peripheral nerves and highlight that the sensory neuron and its surrounding glial coat form a functional unit that orchestrates nerve repair.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Review, Journal: PPARα Agonist Oral Therapy in Diabetic Retinopathy. (Pubmed Central) - Oct 26, 2020 Furthermore, oral administration of selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) agonists may induce hepatic fibroblast growth factor 21 expression, indirectly resulting in retinal protection in animal studies. Our review will enable more comprehensive approaches for understanding protective roles of PPARα for the prevention of DR development.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Preclinical, Journal: Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia. (Pubmed Central) - Oct 24, 2020 Moreover, since fenofibrate is a FDA-approved drug that has an excellent safety profile, our findings suggest that fenofibrate could be a potential pharmacological therapy for GSD Ia in neonatal and pediatric patients as well as for adults. These findings also may apply to non-alcoholic fatty liver disease (NAFLD), which shares similar pathological and metabolic changes with GSD Ia.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Journal: Exercise as medicine for COVID-19: On PPAR with emerging pharmacotherapy. (Pubmed Central) - Oct 23, 2020 Herein, exercise will be compared to fenofibrate as a possible therapeutic strategy to bolster resilience against (and help manage recovery from) COVID-19. This paper will explore the hypothesis that exercise may be a useful adjuvant in a setting of COVID-19 management/rehabilitation due to its effects on PPARα and vascular endothelial function.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Clinical, Journal: High-rate algal pond for removal of pharmaceutical compounds from urban domestic wastewater under tropical conditions. Case study: Santiago de Cali, Colombia. (Pubmed Central) - Oct 21, 2020 Fluticasone/salmeterol carried a higher risk of active TB compared with budesonide/formoterol among COPD patients. Removal efficiencies were high (>70%) for fenofibric acid, ibuprofen, and paracetamol; medium (30-70%) for gabapentin, lamotrigine, fenofibrate, gemfibrozil, diclofenac, ketoprofen, naproxen, and pentoxifylline; and low (50%) in the ecological hazard posed by most of the compounds, although it is important to note that the hazard from gemfibrozil and ibuprofen remained high even after treatment, indicating the need for complementary treatment.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
[VIRTUAL] Fibrates and CKD Patients: A Controversial Issue (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_1054; The long term effects of fibrates versus variable renal derangement are yet to be identified. As to lipid profile, shifting from fibrates to statins led to a stastically significant rise in triglycerides but it's clinical impact is yet to be investigated, so established guidelines might need a revision regarding clinical benefits of fibrates versus it's renal injury.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi, Lacromid (bezafibrate) / Remedica
Clinical, Journal: Additional fibrate treatment in UDCA-refractory PBC patients. (Pubmed Central) - Oct 11, 2020 The data raise the possibility that fenofibrate could be useful in angiosarcoma therapy, especially considering its well-established clinical safety and tolerability profile. In patients with UDCA-refractory PBC, additional fibrate treatment is associated with a higher probability of ALP normalization and a lower risk of cirrhosis development and hepatic deterioration.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Journal: Fenofibrate Reverses Dysfunction of EPCs Caused by Chronic Heart Failure. (Pubmed Central) - Oct 10, 2020 Similar results were also found for tube formation and migration in late EPCs, which were significantly improved by fenofibrate in an AMPK-dependent manner (p < 0.05), suggesting that fenofibrate reversed CACs and late EPC dysfunction in CHF patients. The present findings reveal the potential application of the AMPK agonist fenofibrate to reverse endothelial dysfunction in CHF patients.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Journal: ATM inhibition synergizes with fenofibrate in high grade serous ovarian cancer cells. (Pubmed Central) - Oct 8, 2020 We validated that combined inhibition of ATM and treatment with fenofibrate is synergistic in multiple HGSOC cell lines by inducing senescence. Together, our results suggest that metabolic changes induced by ATM inhibitors are a potential target for the treatment of HGSOC.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi, Frumeron (indapamide) / Remedica
Clinical, Review, Journal: Drug treatments in patients with cardiac diseases and epilepsy. (Pubmed Central) - Oct 8, 2020 Together, our results suggest that metabolic changes induced by ATM inhibitors are a potential target for the treatment of HGSOC. Available data show that the treatment of patients with epilepsy and vascular comorbidities is challenging and requires the appropriate knowledge of pharmacological properties of drugs and drug interactions.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Journal: MiR-21 promotes calcium oxalate-induced renal tubular cell injury by targeting PPARA. (Pubmed Central) - Oct 8, 2020 Suppression of miR-21 by miRNA antagomiR or activation of PPAR-α by its selective agonist fenofibrate significantly reduced renal lipid accumulation and protected against renal injury in vivo...In situ hybridization of biopsy samples from patients with nephrocalcinosis revealed that miR-21 was also significantly upregulated compared with normal kidney tissues from patients with renal cell carcinoma who underwent radical nephrectomy. These results suggested that miR-21 promoted calcium oxalate-induced renal tubular cell injury by targeting PPARA, indicating that miR-21 could be a potential therapeutic target and biomarker for nephrolithiasis.
- |||||||||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
Trial initiation date: XPERTT: Investigating the Effects of QVM149 on MRI Ventilation Defects (clinicaltrials.gov) - Oct 5, 2020 P3, N=48, Not yet recruiting, These results suggested that miR-21 promoted calcium oxalate-induced renal tubular cell injury by targeting PPARA, indicating that miR-21 could be a potential therapeutic target and biomarker for nephrolithiasis. Initiation date: Sep 2020 --> Dec 2020
|